New developments in the management of hepatitis C virus infection: focus on boceprevir.
作者： Xavier Lopez-Labrador , M Berenguer
DOI: 10.2147/BTT.S24413
关键词:
摘要: Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α ribavirin) has effectiveness rate only 40%–50%. Novel virus-specific drugs have recently been designed, multiple compounds are under development. The approval for clinical use direct-acting antivirals in 2011 (boceprevir [BOC] telaprevir, viral NS3 protease inhibitors) increased recovery rates by up to 70%. Therefore, a highly effective envisioned first time. This paper focuses on BOC implementation new BOC-based regimes.
paperity.org参考文章(53)
Gonzàlez-Candelas F, Moya A, López-Labrador Fx, Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates Antiviral Therapy. ,vol. 13, pp. 481- 494 ,(2008)
I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad, J. Schulz, A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. Journal of Viral Hepatitis. ,vol. 19, pp. 1- 26 ,(2012) , 10.1111/J.1365-2893.2012.01590.X
Tarik Asselah, Emilie Estrabaud, Ivan Bieche, Martine Lapalus, Simon De Muynck, Michel Vidaud, David Saadoun, Vassili Soumelis, Patrick Marcellin, Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin Liver International. ,vol. 30, pp. 1259- 1269 ,(2010) , 10.1111/J.1478-3231.2010.02283.X
J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem, C. Sarrazin, Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. Journal of Viral Hepatitis. ,vol. 19, pp. 120- 127 ,(2012) , 10.1111/J.1365-2893.2011.01449.X
Olga M. Klibanov, Stephen B. Vickery, Jacqueline L. Olin, Lisa S. Smith, Shannon H. Williams, Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy. ,vol. 32, pp. 173- 190 ,(2012) , 10.1002/PHAR.1046
G.R. Foster, S. Zeuzem, P. Andreone, S. Pol, E.J. Lawitz, M. Diago, S. Roberts, P.J. Pockros, Z. Younossi, I. Lonjon-Domanec, R. Van Heeswijk, S. de Meyer, D. Luo, S. George, M. Beumont, G. Picchio, 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION Journal of Hepatology. ,vol. 54, ,(2011) , 10.1016/S0168-8278(11)60008-1
Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, Tobias Goeser, Jean-Pierre Bronowicki, Marc Bourlière, Shahin Gharakhanian, Leif Bengtsson, Lindsay McNair, Shelley George, Tara Kieffer, Ann Kwong, Robert S. Kauffman, John Alam, Jean-Michel Pawlotsky, Stefan Zeuzem, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine. ,vol. 360, pp. 1839- 1850 ,(2009) , 10.1056/NEJMOA0807650
Tara L. Kieffer, Christoph Sarrazin, Janice S. Miller, Martin W. Welker, Nicole Forestier, Hendrik W. Reesink, Ann D. Kwong, Stefan Zeuzem, Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. ,vol. 46, pp. 631- 639 ,(2007) , 10.1002/HEP.21781
S. Susser, N. Forestier, J. Vermehren, N. Grigorian, U. Karey, S. Zeuzem, C. Sarrazin, 771 DECLINE OF DETECTABLE RESISTANCE MUTATIONS WITHIN THE HCV NS3 PROTEASE QUASISPECIES DURING LONG-TERM FOLLOW-UP AFTER TREATMENT WITH TELAPREVIR Journal of Hepatology. ,vol. 52, ,(2010) , 10.1016/S0168-8278(10)60773-8
Philippe Halfon, Stephen Locarnini, Hepatitis C virus resistance to protease inhibitors Journal of Hepatology. ,vol. 55, pp. 192- 206 ,(2011) , 10.1016/J.JHEP.2011.01.011